Gastrointestinal Motility Disorder Clinical Trial
Official title:
Gastrointestinal Motor Disorders (Esophageal and Anorectal) in Patients After COVID-19 Infection
The patients who had COVID-19 infection, and after that reported for one of the signs of gastrointestinal disorder (esophageal and anorectal) will be underwent to esophageal and anorectal motor monitoring investigation (HRM manometry) on standard protocol.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | August 31, 2023 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients with esophageal and anorectal symptoms after COVID 19- infection - Patients with worsening of esophageal and anorectal symptom after COVID 19- infection, but who had previously described esophageal and anorectal symptoms Exclusion Criteria: - Other gastrointestinal disease that can influence to results - Gastroesophageal reflux - H. Pylori infection - Bacterial, parasitic, viral and fungal gastrointestinal infection or infestation - Myasthenia - Scleroderma - Diabetes mellitus - Thyroidal hyperfunction |
Country | Name | City | State |
---|---|---|---|
Croatia | Prof.dr.sc. Žarko Babic, FEBGH | Zagreb | Select State |
Lead Sponsor | Collaborator |
---|---|
University Hospital Dubrava |
Croatia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of esophageal parameters 1 on manometry | In esophagus we will measure Upper and lower esophageal sphincter pressure in mmHg. | 120 days | |
Primary | Measurement of esophageal parameters 2 on manometry | In esophagus we will measure Integrated relaxation pressure (IRP) in mmHg. | 120 days | |
Primary | Measurement of esophageal parameters 3 on manometry | In esophagus we will measure Contractile front velocity (CVF) in cm/s. | 120 days | |
Primary | Measurement of esophageal parameters 4 on manometry | In esophagus we will measure Distal contractile integral (DCI) in mmHg.s.cm. | 120 days | |
Primary | Measurement of esophageal parameters 5 on manometry | In esophagus we will measure Distal latency (DL) in seconds. | 120 days | |
Primary | Measurement of esophageal parameters 6 on manometry | In esophagus we will measure Peristaltic brake (BR) in cm. | 120 days | |
Primary | Measurement of anorectal parameters 1 on manometry | On anorectal manometry we will measure Resting test pressure in mmHg. | 2 years | |
Primary | Measurement of anorectal parameters 2 on manometry | On anorectal manometry we will measure Squeeze test pressure in mmHg. | 2 years | |
Primary | Measurement of anorectal parameters 3 on manometry | On anorectal manometry we will measure Endurance squeeze test pressure in mmHg. | 2 years | |
Primary | Measurement of anorectal parameters 4 on manometry | On anorectal manometry we will measure recto-anal inhibitory reflex test (RAIR)- relaxation in percent. | 2 years | |
Primary | Measurement of anorectal parameters 5 on manometry | On anorectal manometry we will measure Push test pressure in mmHg. | 2 years | |
Primary | Measurement of anorectal parameters 6 on manometry | On anorectal manometry we will measure Sensation test with ml in balloon. | 2 years | |
Primary | Measurement of anorectal parameters 7 on manometry | On anorectal manometry we will measure Balloon expulsion test as positive or negative. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04429802 -
The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity
|
N/A | |
Completed |
NCT01644240 -
A Phase 1, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
Terminated |
NCT02573519 -
Gastrointestinal Motility Among Diabetes Patients
|
N/A | |
Recruiting |
NCT04764019 -
Intestinal Dysmotility in Patients With Functional Digestive Symptoms
|
N/A | |
Completed |
NCT03012594 -
Lanreotide in the Treatment of Small Bowel Motility Disorders
|
Phase 2 | |
Not yet recruiting |
NCT05268328 -
The Effect of Foot Reflexology After Cesarean Section
|
||
Completed |
NCT02245165 -
Nitric Oxide Control of Migrating Motor Complex: L-NMMA Effects in Relation to Receptor Blockades
|
Phase 1 | |
Completed |
NCT03552510 -
Oropharyngeal Administration of Mother's Milk in Preterm Infants and Gastrointestinal Motility
|
N/A | |
Completed |
NCT01394055 -
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
|
Phase 1 | |
Active, not recruiting |
NCT00793195 -
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?
|
Phase 2 | |
Recruiting |
NCT04208828 -
IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
|
||
Active, not recruiting |
NCT06347367 -
Short-term Effect of Exercise and Self-manual Approaches to Bloating - Distention
|
N/A | |
Recruiting |
NCT05989763 -
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
|
N/A | |
Completed |
NCT01635608 -
Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water
|
Phase 1 |